Correspondence 0001193125-23-296402 from NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: Dec. 15, 2023 · CIK: 0001936258 · Accession: 0001193125-23-296402
AI Filing Summary & Sentiment
File numbers found in text: 333-275932
Letter
NewAmsterdam Pharma Company N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
December 15, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Jason Drory
Re: NewAmsterdam Pharma Company N.V.
Registration Statement on Form F-3
Filed December 7, 2023
File No. 333-275932
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on December 19, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing.
Respectfully,
NewAmsterdam Pharma Company N.V.
Show Raw Text
CORRESP 1 filename1.htm CORRESP NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands December 15, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Jason Drory Re: NewAmsterdam Pharma Company N.V. Registration Statement on Form F-3 Filed December 7, 2023 File No. 333-275932 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on December 19, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective. We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing. Respectfully, NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Name: Michael Davidson Title: Chief Executive Officer and Executive Director cc: Brian K. Rosenzweig, Covington & Burling LLP